[1]
|
Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Center, 2022, 2: 1-9. doi: 10.1016/j.jncc.2022.02.002 |
[2]
|
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26: 1-133. doi: 10.1089/thy.2015.0020 |
[3]
|
刘延晴, 林岩松. 碘难治性分化型甲状腺癌诊治策略及预后[J]. 中国实用外科杂志, 2019, 39: 216-220. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK201903007.htm |
[4]
|
王任飞, 王勇, 石峰, 等. 碘难治性分化型甲状腺癌的诊治管理共识(2019年版)[J]. 中国癌症杂志, 2019, 29: 476-480. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ201906015.htm |
[5]
|
Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol Metab, 2006, 91: 2892-2829. doi: 10.1210/jc.2005-2838 |
[6]
|
Robin G, Michelle M, Dianne MW, et al. Clinical Practice Guidelines We Can Trust[M]. Washington (DC): National Academies Press (US), 2011. |
[7]
|
Brożek JL, Akl EA, Alonso CP, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines[J]. Allergy, 2009, 64: 669-677. doi: 10.1111/j.1398-9995.2009.01973.x |
[8]
|
Howard B, Mark H, Holger JS, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64: 401-406. doi: 10.1016/j.jclinepi.2010.07.015 |
[9]
|
拜争刚, 刘少堃, 黄崇斐, 等. 定性系统评价证据分级工具: CERQual简介[J]. 中国循证医学杂志, 2015, 15: 1465-1470. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201512015.htm |
[10]
|
Melissa CB, Michelle EK, George PB, et al. AGREE Ⅱ: advancing guideline development, reporting and evaluation in health care[J]. CMAJ, 2010, 182: E839-E842. doi: 10.1503/cmaj.090449 |
[11]
|
张方圆, 沈傲梅, 马婷, 等. 中国癌症症状管理实践指南计划书[J]. 护理研究, 2018, 32: 8-12. https://www.cnki.com.cn/Article/CJFDTOTAL-SXHZ201801005.htm |
[12]
|
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336: 924-926. doi: 10.1136/bmj.39489.470347.AD |
[13]
|
Guyatt GH, Oxman AD, Kunz R, et al. GRADE指南: Ⅱ. 构建问题、确定重要结果[J]. 中国循证医学杂志, 2011, 11: 446-450. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ202112011.htm |
[14]
|
Beverley JS, Barnaby CR, George W, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interven-tions, or both[J]. BMJ, 2017, 358: j4008. |
[15]
|
熊俊, 陈日新. 系统评价/Meta分析方法学质量的评价工具AMSTAR[J]. 中国循证医学杂志, 2011, 11: 1084-1089. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201109016.htm |
[16]
|
Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166: 128-132. |
[17]
|
Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384: 319-328. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60421-9/fulltext |
[18]
|
Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372: 621-630. https://pubmed.ncbi.nlm.nih.gov/25671254/ |
[19]
|
Chi Y, Gao M, Zhang Y, et al. Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase Ⅱ trial[J]. Ann Oncol, 2020, 31: S1347. |
[20]
|
Lin YS, Qin SK, Yang H, et al. Multicenter Randomized Double-Blind Phase Ⅲ Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer[J]. Clin Cancer Res, 2023, 29: 2791-2799. |
[21]
|
Lin Y, Qin S, Li Z, et al. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial[J]. JAMA Oncol, 2021, 8: 242-250. https://pubmed.ncbi.nlm.nih.gov/34913959/ |
[22]
|
Chen J, Ji Q, Bai C, et al. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase Ⅱ Trial[J]. Thyroid, 2020, 30: 1245-1253. |
[23]
|
Brose MS, Robinson BG, Sherman SI, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial[J]. Cancer, 2022, 128: 4203-4212. |
[24]
|
Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines[J]. BMJ, 2016, 353: i2089. https://pubmed.ncbi.nlm.nih.gov/27353417/ |